Catalent’s facilities around the world continue to deliver to our customers and their patients. Catalent’s multiple ongoing investments into expanding our capabilities and capacity to serve our customers are currently proceeding across biologics, cell and gene therapies, oral dose form and inhaled solutions.
We have been declared an essential business by all the national/local governments where we operate, allowing us to sustain full employment for our teams, and are pleased to be in a position to pay a Thank You bonus to our lab, development and production employees who are working on these and other products at our 45+ global facilities.
PARTNERING FOR TREATMENTS
Catalent is proud to support many of the highest profile vaccine programs. We have been awarded work related to nearly 100 unique compounds investigated as potential COVID-19 vaccines and therapies by over 60 customers including antivirals, vaccines, diagnostics and treatments across our biologics, gene therapy, oral technologies, softgel and clinical supply businesses. Due to our investments over the last several years and our financial strength, we were uniquely positioned to provide or build manufacturing capability and capacity for billions of COVID-19 vaccine doses over the next few years, including more than 1 billion vaccine doses this calendar year alone.
Our partnerships include:
- Moderna’s mRNA-based vaccine
- Johnson & Johnson’s vaccine
- AstraZeneca’s vaccine
- Humanigen’s GM-CSF monoclonal antibody therapy
- Arcturus Therapeutics’ mRNA-based vaccine candidate
- Spicona’s virus-like protein-based vaccine candidate
- Ennaid Therapeutics’ antiviral treatment targeted at COVID-19
Please contact us if we can help accelerate your projects to patients.
ABC News recently featured Catalent employees on its Vaccine Watch segment where they discussed their pride in manufacturing the 200 millionth dose of Moderna’s COVID-19 vaccine and celebrated personal milestones. Read the article here.
To address the impact of the outbreak, our senior, multi-disciplinary Coronavirus Response Team, reporting directly to our CEO, continuously monitors the global situation and swiftly executes mitigation activities whenever and wherever required.
To help ensure the safety of our employees and partners and to protect supply to patients, we have taken extensive actions, in line with guidelines issued by the U.S. Centers for Disease Control and Prevention (CDC), the World Health Organization (WHO), and local authorities where we operate. These safety measures include re-emphasizing good hygiene practices to all, severely restricting visitor access to our sites, reorganizing our workflows where permitted to maximize social distancing, limiting employees to only business-critical travel (where permitted by local government policy), facilitating safer alternatives for travel to and from work, and, wherever possible, employing remote-working strategies.
SUPPLY CHAIN IMPACT
We continue to survey deep into our supply chain and have not identified any significant risk, delay, or concern that may have a substantial effect on delivery of any product or clinical trial supplies. We have adopted specific procedures to minimize and manage any future disruption to our ongoing operations. These include expanded safety stocks of raw materials and Personal Protective Equipment across our network, as well as ongoing monitoring of our suppliers’ stock levels to assure future deliveries.
Our existing Standard Operating Procedures, which are consistent with current Good Manufacturing Practices, ensure the integrity of our supply against any contamination. We have added a detailed response plan to manage any impact of the virus on employee health, site operations, and product supply, including immediate assessment of the health of employees reporting symptoms, comprehensive risk assessment of any impact to quality, additional cleaning protocols, and alternative shift patterns to compensate should fewer employees be available.
We will notify and consult with our partners should we foresee any impact on supply.
Customers who may have specific questions about a product or project, or anyone requiring additional information regarding a potential or planned visit to a Catalent facility should contact their usual Catalent contact or any customer service representative.
As we navigate the COVID-19 pandemic, we will continue to put the Patient First and do everything possible to keep our people safe and healthy, while we continue to strive to meet the needs and expectations of our customers.
Last update: August 20, 2021